Rare genetic disorders more complex than thought
Study reveals that common genetic variants could affect the risk of rare developmental disorders
Researchers have found that the genetic causes of rare neurodevelopmental disorders vary more than previously thought. The study from Wellcome Sanger Institute scientists and their collaborators discovered that serious rare disorders can be affected by combinations of common genetic variants, rather than solely individual rare variants that damage single genes.
The study published today (26 September) in Nature will help researchers understand how an individual’s whole genetic make-up can modify the effect of rare damaging variants typically thought to cause these developmental disorders. They also revealed that common genetic variants known to increase the risk of conditions such as schizophrenia also increased the risk of rare developmental disorders.
Thousands of babies are born each year who do not develop normally because of their particular genetic makeup. Those with neurodevelopmental disorders can have difficulties in learning or language, or conditions such as autism. The Deciphering Developmental Disorders (DDD) study aims to find diagnoses* for these children with as yet unknown developmental disorders, and to understand the causes of these conditions.
Previously it was thought that common genetic variants contribute to common disorders only, such as diabetes or heart disease, but that rare disorders were caused solely by highly damaging mutations in single genes. However, it is well known that different patients who have damaging mutations in the same gene often have some different symptoms. The DDD researchers have tried to understand why.
The researchers studied the genomes of nearly 7,000 children in the DDD study who had a variety of neurodevelopmental disorders and compared them with healthy control individuals. Using Genome-Wide Association Studies (GWAS) the team tested 4 million common genetic variants for association with neurodevelopmental disorders. Surprisingly, the researchers found that these common variations also affected the risk of rare neurodevelopmental disorders.
“Until now, rare developmental disorders have been thought to be caused by a single gene having a huge effect, but our study shows that this might not be the whole story. We discovered that common variants that work together to influence common diseases such as schizophrenia also seem to contribute to rare developmental disorders. These variants could lead to changes during brain development, that could cause a range of common or rare conditions.”
Mari Niemi First author on the paper from the Wellcome Sanger Institute
“This is the first-ever large-scale study of the role of common genetic variants in rare neurodevelopmental disorders, and was only possible due to the large cohort of patients in the DDD study. This shows that the genetics of rare diseases are more complicated than originally thought, and we hope it will change how researchers and clinicians think of rare versus common diseases.”
Dr Hilary Martin An author on the paper from the Wellcome Sanger Institute
“Our study shows for the first time that common genetic variants could affect the risk of rare developmental disorders, and some of their characteristics. As we learn more about the genetic causes of both rare and common diseases, it is increasingly clear that many different types of genetic variation play important roles in all cases.”
Dr Jeffrey Barrett A senior author who carried out the work while at the Wellcome Sanger Institute
Mari Niemi et al. (2018) Common genetic variants contribute to risk of severe neurodevelopmental disorders. Nature DOI: 10.1038/s41586-018-0566-4
*Background to Deciphering Developmental Disorders
Correct diagnoses for families with rare developmental disorders are crucial for helping them understand what caused the disorder. Diagnoses also allow families with the same genetic conditions to meet up and access support, and can help inform treatment. In addition, diagnoses help improve prediction of the risk for any future children in that family.
The DDD study was supported by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. Please see the paper for further funders.
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. To celebrate its 25th year in 2018, the Institute is sequencing 25 new genomes of species in the UK. Find out more at www.sanger.ac.uk or follow @sangerinstitute on Twitter, Facebook and LinkedIn
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate. wellcome.org
Related blog posts
What is a genetic disorder?
A genetic disorder is a disease that is caused by a change, or mutation, in an individual’s DNA sequence.
What is genetic testing?
Genetic testing is an incredibly useful tool for identifying changes or mutations in DNA that could lead to genetic disease.
What is a complex disease?
Many common diseases are influenced by a combination of multiple genes and environmental factors. These diseases are referred to as complex ...
26 Jan 2023
‘Collateral damage’ from normal cell function may cause mutations that play a role in cancer
APOBEC1 enzyme likely responsible for two mutational signatures found in many cancers in small intestine
19 Jan 2023
Bowel cancer mutations that impact immunotherapy identified
Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.